会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 4. 发明申请
    • EYE THERAPY SYSTEM
    • 眼睛治疗系统
    • US20100094197A1
    • 2010-04-15
    • US12570959
    • 2009-09-30
    • John MarshallAli HusseinDavid Muller
    • John MarshallAli HusseinDavid Muller
    • A61F9/013
    • A61F9/008A61F9/0079A61F9/009A61F2009/00853A61F2009/00872
    • In a system for stabilizing a pattern of structural changes in corneal fibrils, an eye treatment system causes corneal fibrils of a cornea of an eye to transition from a first structure to a second structure. An application device applies a cross-linking element to the corneal fibrils. An activating device applies an initiating element to the corneal fibrils and activates the cross-linking element. The cross-linking element causes cross-linking in the corneal fibrils to preserve the second structure of the corneal fibrils. Another application device may apply a cross-linking breaker to the corneal fibrils. The cross-linking breaker halts or reverses at least partially the cross-linking in the corneal fibrils. Another activating device applies an initiating element to the corneal fibrils and activates the cross-linking breaker. Advantageously, the cross-linking breaker provides greater control over the amount and progress of cross-linking that occurs in the corneal fibrils.
    • 在用于稳定角膜原纤维结构变化的模式的系统中,眼睛治疗系统使眼睛角膜的角膜原纤维从第一结构转变到第二结构。 应用装置将交联元件应用于角膜原纤维。 激活装置将起始元件施加到角膜原纤维并激活交联元件。 交联元件引起角膜原纤维中的交联以保留角膜原纤维的第二结构。 另一应用装置可以将交联断路器应用于角膜原纤维。 交联断路器至少部分地停止或逆转角膜原纤维中的交联。 另一激活装置将起始元件施加到角膜原纤维并激活交联断路器。 有利地,交联断路器对角膜原纤维中发生的交联的量和进展提供更大的控制。
    • 5. 发明授权
    • Eye therapy
    • 眼科治疗
    • US08574277B2
    • 2013-11-05
    • US12909228
    • 2010-10-21
    • David MullerJohn MarshallMarc D. Friedman
    • David MullerJohn MarshallMarc D. Friedman
    • A61N5/06A61F9/00
    • A61N5/062A61F9/0008A61F9/013A61K31/14
    • Embodiments apply a cross-linking agent to a region of corneal tissue. The cross-linking agent improves the ability of the corneal tissue to resist undesired structural changes. For example, the cross-linking agent may be Riboflavin or Rose Bengal, and the initiating element may be photoactivating light, such as ultraviolet (UV) light. In these embodiments, the photoactivating light initiates cross-linking activity by irradiating the applied cross-linking agent to release reactive oxygen radicals in the corneal tissue. The cross-linking agent acts as a sensitizer to convert O2 into singlet oxygen which causes cross-linking within the corneal tissue. The rate of cross-linking in the cornea is related to the concentration of O2 present when the cross-linking agent is irradiated with photoactivating light. Accordingly, the embodiments control the concentration of O2 during irradiation to increase or decrease the rate of cross-linking and achieve a desired amount of cross-linking.
    • 实施例将交联剂应用于角膜组织的区域。 交联剂改善了角膜组织抵抗不良结构变化的能力。 例如,交联剂可以是核黄素或玫瑰红,并且起始元件可以是光活化的光,例如紫外(UV)光。 在这些实施方案中,光活化光通过照射施加的交联剂以释放角膜组织中的活性氧自由基引发交联活性。 交联剂作为敏化剂将O 2转化成单线态氧,导致角膜组织内的交联。 角膜中的交联速率与交联剂用光活化光照射时存在的O 2浓度有关。 因此,实施例控制照射期间的O 2浓度以增加或降低交联速率并达到所需量的交联。